Alnylam, Israel's Medison partner to commercialize Onpattro, RNAi portfolio
Alnylam Pharmaceuticals and Israel's Medison Pharma announced an exclusive agreement to commercialize Onpattro as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. "Our partnership with Medison marks an important step in our global commercial expansion and signals our intent to ensure that patients suffering from serious rare diseases have access to our medicines, regardless of location," said Theresa Heggie, SVP and Head of Europe, Middle East and Africa, and Canada, Alnylam Pharmaceuticals. The agreement between Alnylam and Medison includes Onpattro, approved in the European Union in August 2018 for the treatment of hATTR amyloidosis in adults with stage one or stage two polyneuropathy; givosiran, a late-stage investigational RNAi therapeutic for the treatment of acute hepatic porphyria; and lumasiran, a late-stage investigational RNAi therapeutic for the treatment of Primary Hyperoxaluria Type 1. These medicines are not currently approved for use in Israel and givosiran and lumasiran have not yet been approved by any regulatory authority, Alnylam noted.